We serve Chemical Name:2,3,5,6-tetrafluoroterephthalaldehyde CAS:3217-47-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3,5,6-tetrafluoroterephthalaldehyde
CAS.NO:3217-47-8
Synonyms:2,3,5,6-Tetrafluorotelephtal aldehyde;2,3,5,6-tetrafluoroterephthaldehyde;2,3,5,6-tetrafluorobenzene-1,4-dicarbaldehyde;2,3,5,6-tetrafluorotelephthalaldehyde;AC-775;tetrafluoroterephthaldehyde
Molecular Formula:C8H2F4O2
Molecular Weight:206.09400
HS Code:2913000090
Physical and Chemical Properties:
Melting point:130-132 ºC
Boiling point:252.566ºC at 760 mmHg
Density:1.59g/cm3
Index of Refraction:1.525
PSA:34.14000
Exact Mass:205.99900
LogP:1.86800
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,3,5,6-Tetrafluorotelephtal aldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tetrafluoroterephthaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3,5,6-Tetrafluorotelephtal aldehyde Use and application,2,3,5,6-tetrafluorobenzene-1,4-dicarbaldehyde technical grade,usp/ep/jp grade.
Related News: Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv. 2-phenyl-4-methyl-5,6-dimorpholinopyrimidine manufacturers Walmsley’s background in consumer health—and lack of prior experience in pharma—has reportedly been targeted by Elliott in the investment firm’s secret push for a new boss at GSK. 3-(3,4-Dichlorbenzyl)-2-methyl-4-oxo-1-penten suppliers “We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.” 3-(3-hydroxy-2-methylheptan-2-yl)-6-methyl-5-phenyl-2,3-dihydro-4H-1,3-oxazin-4-one vendor & factory Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv.,“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.”
